FreeTheAI

Alector Licenses Preclinical Parkinson's Program AL050 to Genentech

BullishMedium impact
ALEC$2.08 2.97%

Biotechnology firm Alector, Inc. (ALEC) has entered into an agreement with Genentech to license its preclinical Parkinson's disease candidate, AL050. Under the terms of the deal, Genentech will take responsibility for the future development and commercialization of the program. In exchange, Alector receives a significant upfront payment along with eligibility for future milestone payments. Shares of Alector traded up 2.97% to $2.08 following the news.

To support the program's underlying intellectual property, Alector paid $15 million to Spur for engineered GCase rights related to AL050. This intellectual property license secures the necessary rights through September 30, 2026. As part of that arrangement, Alector agreed to share mid-teen sublicense income with Spur in addition to pass-through royalty payments.

Moving forward, investors will be watching for clinical progress as Genentech advances the AL050 program toward potential human trials. Market participants will also monitor any upcoming milestone payments or secondary sublicense revenue that could impact Alector's balance sheet.

Key points

  • Alector, Inc. licensed its preclinical Parkinson's disease program AL050 to Genentech, which will handle development and commercialization.
  • Alector received a large upfront payment and remains eligible to collect potential future milestone payments.
  • Alector paid $15 million to Spur to license engineered GCase IP for AL050, securing intellectual property rights through Sept. 30, 2026.
  • Alector agreed to pay Spur mid-teen sublicense income along with pass-through royalties under the IP deal.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is the agreement between Alector and Genentech?

Alector licensed its preclinical Parkinson's program AL050 to Genentech. Genentech will develop and commercialize the candidate, while Alector received a large upfront payment and potential milestones.

How much did Alector pay Spur for GCase rights?

Alector paid $15 million to Spur for engineered GCase IP for AL050. The agreement secures IP rights through Sept. 30, 2026, with Alector sharing mid-teen sublicense income and pass-through royalties.